Phase II Trial of Droxidopa in Fibromyalgia is Granted MHRA Approval

by General Manager on 28th July 2008

in All ME/ Chronic Fatigue Syndrome And Fibromyalgia News, Research

Chelsea Therapeutics Granted MHRA Approval to Begin Phase II Trial of Droxidopa in Fibromyalgia
FOXBusiness - Jul 23, 2008
Fibromyalgia is a chronic and debilitating condition that is characterized by widespread pain and stiffness throughout the body, accompanied by severe

 

Leave a Comment

Previous post: Cognitive Behaviour Therapy (CBT) scheme threatens to waste millions with no proven benefits

Next post: NEW: Exercise And Chronic Fatigue Syndrome – Anne-Maree’s Experience